Advances in novel devices for the treatment of heart failure

Heart Fail Rev. 2023 Mar;28(2):331-345. doi: 10.1007/s10741-022-10293-z. Epub 2023 Feb 16.

Abstract

Heart failure (HF) is one of the leading causes of global health impairment. Current drugs are still limited in their effectiveness in the treatment and reversal of HF: for example, drugs for acute HF (AHF) help to reduce congestion and relieve symptoms, but they do little to improve survival; most conventional drugs for HF with preserved ejection fraction (HFpEF) do not improve the prognosis; and drugs have extremely limited effects on advanced HF. In recent years, progress in device therapies has bridged this gap to a certain extent. For example, the availability of the left ventricular assist device has brought new options to numerous advanced HF patients. In addition to this recognizable device, a range of promising novel devices with preclinical or clinical trial results are emerging that seek to treat or reverse HF by providing circulatory support, repairing structural abnormalities in the heart, or providing electrical stimulation. These devices may be useful for the treatment of HF. In this review, we summarized recent advances in novel devices for AHF, HFpEF, and HF with reduced ejection fraction (HFrEF) with the aim of providing a reference for clinical treatment and inspiration for novel device development.

Keywords: Acute heart failure; Chronic heart failure; Device therapy; Ventricular assist device.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Heart Failure*
  • Humans
  • Prognosis
  • Stroke Volume / physiology
  • Ventricular Dysfunction, Left*
  • Ventricular Function, Left / physiology